品质为先。

     

APAC MARKETS

我们设法促进高度专业化和具有科学价值的领域的发展,以提高医疗保健的标准。

发现更多关于美纳里尼集团的信息

30 多年来,美纳里尼一直致力于推动研发,为受严重健康问题影响的患者提供创新且有效的药物和医疗保健解决方案。

在13个主要市场获取进入亚太地区所有主要市场的单点式入口。

分享您的合作意向

充分利用我们的全渠道方法使您的品牌在亚太地区增长。

MARKETS

亚太地区的医疗行业正在快速增长。美纳里尼亚太隶属于世界领先的意大利生物制药公司,在该地区13个主要市场拥有强大的布局。

作为众多全球医疗保健公司的首选合作伙伴,我们参与整个药品开发生命周期,挖掘增长机会并扩大其品牌影响力。在此过程中,我们还为医务工作者和患者提供优质医疗产品和技术支持,以提高标准并为未来缔造健康生活。

我们的亚太地区总部

A. MENARINI ASIA-PACIFIC HOLDINGS PTE LTD
A. MENARINI ASIA-PACIFIC PRIVATE LIMITED
A. MENARINI SINGAPORE PTE LTD
A. MENARINI BIOMARKERS SINGAPORE PTE LTD

30 Pasir Panjang Road,
Mapletree Business City,
#08-32 Singapore 117440
Tel: +65-6494-7200
Fax: +65-6999-1787

 

2022

2022

  • 2022 - 09 - 20

    美纳里尼与赛生药业签署独家许可协议 - 在华开发和商业化Vaborem®以治疗耐药菌感染

    新加坡和香港, 2022年9月20日 /美通社/ -- 美纳里尼集团(The Menarini Group)旗下美纳里尼亚太公司(A. Menarini Asia-Pacific Holdings Pte. Ltd.)与赛生药业控股有限公司就在华开发和商业化Vaborem®(美罗培南和韦博巴坦)签署了一项独家许可协议。该方案旨在扩大细菌耐药的选择,以应对耐药菌感染尤其是碳青霉烯类药物耐药的肠杆菌科细菌(CRE)对公共卫生构成的威胁。目前,Vaborem®在欧盟被用于治疗各种适应症,包括复杂性尿路感染(cUTI)、复杂性腹腔感染(cIAI)和医院获得性肺炎(HAP),在美国被批准用于治疗cUTI。
  • 2022 - 08 - 24

    Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced Metastatic Breast Cancer

    FLORENCE, Italy and NEW YORK, NY, August 19, 2022 -- The Menarini Group (“Menarini”), a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics (“Stemline”), a wholly-owned subsidiary of the Menarini Group, today announced that EMA has validated the Marketing Authorization Application (MAA) for elacestrant, a selective estrogen receptor degrader (SERD), for patients with ER+/HER2- advanced or metastatic breast cancer. Validation of the application confirms the submission is complete and begins EMA’s centralized review procedure.
  • 2022 - 08 - 11

    Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

    FLORENCE, Italy and NEW YORK, NY, August 11, 2022 -- The Menarini Group (“Menarini”), a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics (“Stemline”), a wholly-owned subsidiary of Menarini Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for elacestrant, an investigational selective estrogen receptor degrader (SERD), for patients with ER+/HER2- advanced or metastatic breast cancer. The FDA has granted the application Priority Review and assigned a PDUFA date of February 17, 2023.
  • 2022 - 08 - 02

    Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

    PHILADELPHIA, PA and FLORENCE, Italy— August 02, 2022—Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, and The Menarini Group (“Menarini”) today announced a clinical trial collaboration and supply agreement for Menarini’s oral selective estrogen receptor degrader (SERD), elacestrant.
  • 2022 - 07 - 22

    Australian sports stars shine at XXVI Fair Play Menarini International Awards

    22 July 2022 | Sydney, Australia – A. Menarini Australia and New Zealand (Menarini ANZ) welcomes the announcement of two leading Australian sports stars, Ian Thorpe AM and Casey Stoner AM, as winners of the XXVI Fair Play Menarini International Awards. Now in its 26th year, the Fair Play Menarini International Award aims to recognise leaders in sport who have demonstrated the values of fair play – ethics, loyalty and respect – over the course of their careers.
  • 2022 - 07 - 21

    Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy

    NEWTON, Mass. and FLORENCE, Italy, – July 21, 2022 – Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today announced that the European Commission (EC) has granted Marketing Authorisation for NEXPOVIO® (selinexor), a first-in-class, oral exportin 1 (XPO1) inhibitor, in combination
  • 2022 - 07 - 08

    Sport’s finest gather under the stars for the grand finale of the XXVI Fair Play Menarini International Award

    FLORENCE, 8th July 2022 – Intense emotions and immense satisfaction were in the air during the final event of the XXVI Fair Play Menarini International Award. Yesterday evening, the award ceremony for the winners of the 2022 edition in Castiglion Fiorentino (Arezzo) drew an enjoyable end to this celebration of the values of sportsmanship, organised by the Fair Play Menarini Foundation.
  • 2022 - 06 - 06

    Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

    Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an investigational oral selective estrogen receptor degrader (SERD), vs. investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC)